MedTrace Logo

Clearance Mechanisms in Atypical Neurodegenerative Diseases

NCT05317871 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2023-03-09

No results posted yet for this study

Summary

The project PeptiClear aims to investigate whether the blood-brain-barrier (BBB) and the glymphatic system are compromised in atypical neurodegenerative diseases, and whether Alzheimer´s disease (AD)-related copathology, vascular lesions or sleep disturbances modify the clinical picture or structural and/or functional features of the diseases.

Conditions

Sponsors & Collaborators

  • Ludwig-Maximilians - University of Munich

    lead OTHER

Principal Investigators

  • Robert Perneczky, Prof. Dr. · Klinik und Poliklinik für Psychiatrie und Psychotherapie des LMU Klinikums

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2024-04-30
Completion
2024-04-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05317871 on ClinicalTrials.gov